Pathos AI raises $237 million in Series E funding to fund drug development platform

Statements (5)

1. ▲ Bullish

   Pathos AI raised $237 million in a Series E funding round at a $3 billion valuation.

   endpoints.newsOct 23, 2026 13:00 UTCHigh importance
2. ▲ Bullish

   Pathos AI signed a partnership with Bristol Myers for neuro applications.

   endpoints.newsOct 23, 2026 13:00 UTC
3. ▲ Bullish

   Pathos AI raised $237 million in Series E financing to fund its drug development platform.

   businesswire.comOct 23, 2026 13:00 UTCHigh importance
4. ● Neutral

   Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb and Tempus AI to advance AI-driven drug development.

   businesswire.comOct 23, 2026 13:00 UTCHigh importance
5. ▲ Bullish

   Pathos raises $237 million in funding from a deal involving Tempus dataset, AI analysis, and BMS drug development.

   statnews.comOct 23, 2026 13:00 UTCHigh importance